Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget. 2017;8:30908-30921 pubmed publisher

Due S, Watson D, Bastian I, Eichelmann A, Hussey D. Oestrogen Receptor Isoforms May Represent a Therapeutic Target in Oesophageal Adenocarcinoma. Cancers (Basel). 2022;14: pubmed publisher

Fernández Duran I, Quintanilla A, Tarrats N, Birch J, Hari P, Millar F, et al. Cytoplasmic innate immune sensing by the caspase-4 non-canonical inflammasome promotes cellular senescence. Cell Death Differ. 2022;29:1267-1282 pubmed publisher

Kim C, Jin J, Ye Z, Jadhav R, Gustafson C, Hu B, et al. Histone deficiency and accelerated replication stress in T cell aging. J Clin Invest. 2021;131: pubmed publisher

Singh S, Abu Zaid A, Lin W, Low J, Abdolvahabi A, Jin H, et al. 17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma. iScience. 2021;24:101996 pubmed publisher

Gain C, Malik S, Bhattacharjee S, Ghosh A, Robertson E, Das B, et al. Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway. PLoS Pathog. 2020;16:e1008105 pubmed publisher

Chollat Namy M, Ben Safta Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:695 pubmed publisher

Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt M, Hermanns H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38:397 pubmed publisher

Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019;38: pubmed publisher

Liu B, Yi J, Yang X, Liu L, Lou X, Zhang Z, et al. MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner. Oncogene. 2019;38:2501-2515 pubmed publisher

Komori H, Goto Y, Kurayoshi K, Ozono E, Iwanaga R, Bradford A, et al. Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes. Sci Rep. 2018;8:8438 pubmed publisher

Giono L, Resnick Silverman L, Carvajal L, St Clair S, Manfredi J. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase. Oncogene. 2017;36:6762-6773 pubmed publisher

Fumagalli A, Drost J, Suijkerbuijk S, van Boxtel R, de Ligt J, Offerhaus G, et al. Genetic dissection of colorectal cancer progression by orthotopic transplantation of engineered cancer organoids. Proc Natl Acad Sci U S A. 2017;114:E2357-E2364 pubmed publisher

Liu T, Krysiak K, Shirai C, Kim S, Shao J, Ndonwi M, et al. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells. PLoS ONE. 2017;12:e0170470 pubmed publisher

Castellini L, Moon E, Razorenova O, Krieg A, von Eyben R, Giaccia A. KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res. 2017;45:3674-3692 pubmed publisher

De Smet F, Saiz Rubio M, Hompes D, Naus E, De Baets G, Langenberg T, et al. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. J Pathol. 2017;242:24-38 pubmed publisher

Gotoh T, Kim J, Liu J, Vila Caballer M, Stauffer P, Tyson J, et al. Model-driven experimental approach reveals the complex regulatory distribution of p53 by the circadian factor Period 2. Proc Natl Acad Sci U S A. 2016;113:13516-13521 pubmed

Qi D, Cobrinik D. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene. 2017;36:1760-1769 pubmed publisher

Nonomiya Y, Noguchi K, Tanaka N, Kasagaki T, Katayama K, Sugimoto Y. Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells. Cancer Sci. 2016;107:1877-1887 pubmed publisher

Zhuang J, Kamp W, Li J, Liu C, Kang J, Wang P, et al. Forkhead Box O3A (FOXO3) and the Mitochondrial Disulfide Relay Carrier (CHCHD4) Regulate p53 Protein Nuclear Activity in Response to Exercise. J Biol Chem. 2016;291:24819-24827 pubmed

Minemura H, Takagi K, Sato A, Takahashi H, Miki Y, Shibahara Y, et al. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Sci. 2016;107:1898-1908 pubmed publisher

Kozakai Y, Kamada R, Furuta J, Kiyota Y, Chuman Y, Sakaguchi K. PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin. Sci Rep. 2016;6:33272 pubmed publisher

Tavana O, Li D, Dai C, Lopez G, Banerjee D, Kon N, et al. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med. 2016;22:1180-1186 pubmed publisher

Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, et al. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. 2017;36:1678-1686 pubmed publisher

Bauer M, Joerger A, Fersht A. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016;113:E5271-80 pubmed publisher

Park J, Yang S, Park J, Ka S, Kim J, Kong Y, et al. Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Nat Commun. 2016;7:12513 pubmed publisher

Adriaens C, Standaert L, Barra J, Latil M, Verfaillie A, Kalev P, et al. p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nat Med. 2016;22:861-8 pubmed publisher

Itahana Y, Zhang J, Göke J, Vardy L, Han R, Iwamoto K, et al. Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells. Sci Rep. 2016;6:28112 pubmed publisher

Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu G, et al. Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. elife. 2016;5: pubmed publisher

D Brot A, Kurtz P, Regan E, Jakubowski B, Abrams J. A platform for interrogating cancer-associated p53 alleles. Oncogene. 2017;36:286-291 pubmed publisher

Chen S, FORRESTER W, Lahav G. Schedule-dependent interaction between anticancer treatments. Science. 2016;351:1204-8 pubmed publisher

Frum R, Love I, Damle P, Mukhopadhyay N, Palit Deb S, Deb S, et al. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination. Mol Cancer Res. 2016;14:423-36 pubmed publisher

Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17:349-66 pubmed publisher

Kanderová V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016;15:1246-61 pubmed publisher

Berges C, Chatterjee M, Topp M, Einsele H. Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells. Immunol Res. 2016;64:687-98 pubmed publisher

Du C, Wu H, Leng R. UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation. Oncotarget. 2016;7:2823-36 pubmed publisher

Pages M, Lacroix L, Tauziède Espariat A, Castel D, Daudigeos Dubus E, Ridola V, et al. Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta Neuropathol Commun. 2015;3:85 pubmed publisher

Kanu N, Zhang T, Burrell R, Chakraborty A, Cronshaw J, DaCosta C, et al. RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. Oncogene. 2016;35:4009-19 pubmed publisher

Shatz M, Shats I, Menendez D, Resnick M. p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways. Oncotarget. 2015;6:16963-80 pubmed

Zhu J, Zhao C, Zhuang T, Jonsson P, Sinha I, Williams C, et al. RING finger protein 31 promotes p53 degradation in breast cancer cells. Oncogene. 2016;35:1955-64 pubmed publisher

Neo S, Itahana Y, Alagu J, Kitagawa M, Guo A, Lee S, et al. TRIM28 Is an E3 Ligase for ARF-Mediated NPM1/B23 SUMOylation That Represses Centrosome Amplification. Mol Cell Biol. 2015;35:2851-63 pubmed publisher

Kloet D, Polderman P, Eijkelenboom A, Smits L, van Triest M, van den Berg M, et al. FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21(Cip1/Waf1). Biochem J. 2015;469:289-98 pubmed publisher

Andries V, Vandepoele K, Staes K, Berx G, Bogaert P, Van Isterdael G, et al. NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest. BMC Cancer. 2015;15:391 pubmed publisher

Wright J, Atwan Z, Morris S, Leppard K. The Human Adenovirus Type 5 L4 Promoter Is Negatively Regulated by TFII-I and L4-33K. J Virol. 2015;89:7053-63 pubmed publisher

Isogai T, van der Kammen R, Innocenti M. SMIFH2 has effects on Formins and p53 that perturb the cell cytoskeleton. Sci Rep. 2015;5:9802 pubmed publisher

Drost J, van Jaarsveld R, Ponsioen B, Zimberlin C, van Boxtel R, Buijs A, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43-7 pubmed publisher

Seiki T, Nagasaka K, Kranjec C, Kawana K, Maeda D, Nakamura H, et al. HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy. BMC Cancer. 2015;15:230 pubmed publisher

Stolz A, Ertych N, Bastians H. A phenotypic screen identifies microtubule plus end assembly regulators that can function in mitotic spindle orientation. Cell Cycle. 2015;14:827-37 pubmed publisher

Butin Israeli V, Adam S, Jain N, Otte G, Neems D, Wiesmüller L, et al. Role of lamin b1 in chromatin instability. Mol Cell Biol. 2015;35:884-98 pubmed publisher

Ghorbani A, Jeddi Tehrani M, Saidpour A, Safa M, Bayat A, Zand H. PI3K/AKT and Mdm2 activation are associated with inhibitory effect of cAMP increasing agents on DNA damage-induced cell death in human pre-B NALM-6 cells. Arch Biochem Biophys. 2015;566:58-66 pubmed publisher

Park J, Lee S, Yang S, Yoo H, Park J, Seong M, et al. Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage. Nat Commun. 2014;5:5483 pubmed publisher

Idogawa M, Ohashi T, Sugisaka J, Sasaki Y, Suzuki H, Tokino T. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget. 2014;5:7540-8 pubmed

Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, et al. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone. PLoS ONE. 2014;9:e105526 pubmed publisher

Li L, Wu P, Lee J, Li P, Hsieh W, Ho C, et al. Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells. PLoS ONE. 2014;9:e104203 pubmed publisher

Oi N, Yuan J, Malakhova M, Luo K, Ryu J, Zhang L, et al. Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene. 2015;34:2660-71 pubmed publisher

Yamauchi T, Nishiyama M, Moroishi T, Yumimoto K, Nakayama K. MDM2 mediates nonproteolytic polyubiquitylation of the DEAD-Box RNA helicase DDX24. Mol Cell Biol. 2014;34:3321-40 pubmed publisher

Luo X, Suzuki M, Ghandhi S, Amundson S, Boothman D. ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence. PLoS ONE. 2014;9:e99983 pubmed publisher

Mahadevan D, Morales C, Cooke L, Manziello A, Mount D, Persky D, et al. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS ONE. 2014;9:e95184 pubmed publisher

Gad H, Koolmeister T, Jemth A, Eshtad S, Jacques S, Ström C, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014;508:215-21 pubmed publisher

Facciuto F, Bugnon Valdano M, Marziali F, Massimi P, Banks L, Cavatorta A, et al. Human papillomavirus (HPV)-18 E6 oncoprotein interferes with the epithelial cell polarity Par3 protein. Mol Oncol. 2014;8:533-43 pubmed publisher

Meijer A, Kruyt F, van der Zee A, Hollema H, Le P, Ten Hoor K, et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer. 2013;109:2685-95 pubmed publisher

Gubanova E, Issaeva N, Gokturk C, Djureinovic T, Helleday T. SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle. 2013;12:3770-80 pubmed publisher

Sy S, Jiang J, O W, Deng Y, Huen M. The ubiquitin specific protease USP34 promotes ubiquitin signaling at DNA double-strand breaks. Nucleic Acids Res. 2013;41:8572-80 pubmed publisher

Brochier C, Dennis G, Rivieccio M, McLaughlin K, Coppola G, Ratan R, et al. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci. 2013;33:8621-32 pubmed publisher

Ranaweera R, Yang X. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. J Biol Chem. 2013;288:18939-46 pubmed publisher

Moreno A, Soleto I, García Sanz P, Moreno Bueno G, Palmero I. ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. Oncogene. 2014;33:1945-53 pubmed publisher

Kojima K, Kornblau S, Ruvolo V, Dilip A, Duvvuri S, Davis R, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013;121:4166-74 pubmed publisher

Andrews P, He Z, Tzenov Y, Popadiuk C, Kao K. Evidence of a novel role for Pygopus in rRNA transcription. Biochem J. 2013;453:61-70 pubmed publisher

Jullien L, Mestre M, Roux P, Gire V. Eroded human telomeres are more prone to remain uncapped and to trigger a G2 checkpoint response. Nucleic Acids Res. 2013;41:900-11 pubmed publisher

Li X, Wu L, Corsa C, Kunkel S, Dou Y. Two mammalian MOF complexes regulate transcription activation by distinct mechanisms. Mol Cell. 2009;36:290-301 pubmed publisher

Wolff S, Erster S, Palacios G, Moll U. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008;18:733-44 pubmed publisher

Sakasai R, Tibbetts R. RNF8-dependent and RNF8-independent regulation of 53BP1 in response to DNA damage. J Biol Chem. 2008;283:13549-55 pubmed publisher

Román Rosales A, Garcia Villa E, Herrera L, Gariglio P, Diaz Chavez J. Mutant p53 gain of function induces HER2 over-expression in cancer cells. BMC Cancer. 2018;18:709 pubmed publisher

Liao P, Zeng S, Zhou X, Chen T, Zhou F, Cao B, et al. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Mol Cell. 2017;68:1134-1146.e6 pubmed publisher

Parvathaneni S, Lu X, Chaudhary R, Lal A, Madhusudan S, Sharma S. RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner. Oncotarget. 2017;8:75924-75942 pubmed publisher

Thaler S, Schmidt M, Roβwag S, Thiede G, Schad A, Sleeman J. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget. 2017;8:72281-72301 pubmed publisher

Pacini L, Ceraolo M, Venuti A, Melita G, Hasan U, Accardi R, et al. UV Radiation Activates Toll-Like Receptor 9 Expression in Primary Human Keratinocytes, an Event Inhibited by Human Papillomavirus 38 E6 and E7 Oncoproteins. J Virol. 2017;91: pubmed publisher

Ghosh S, Salot S, Sengupta S, Navalkar A, Ghosh D, Jacob R, et al. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis. Cell Death Differ. 2017;24:1784-1798 pubmed publisher

Al Khalaf H, Amir M, Al Mohanna F, Tulbah A, Al Sayed A, Aboussekhra A. Obesity and p16INK4A Downregulation Activate Breast Adipocytes and Promote Their Protumorigenicity. Mol Cell Biol. 2017;37: pubmed publisher

Marmisolle I, Martínez J, Liu J, Mastrogiovanni M, Fergusson M, Rovira I, et al. Reciprocal regulation of acetyl-CoA carboxylase 1 and senescence in human fibroblasts involves oxidant mediated p38 MAPK activation. Arch Biochem Biophys. 2017;613:12-22 pubmed publisher

Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, et al. ?40p53? suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. J Cell Sci. 2017;130:614-625 pubmed publisher

Sokolova M, Turunen M, Mortusewicz O, Kivioja T, Herr P, Vähärautio A, et al. Genome-wide screen of cell-cycle regulators in normal and tumor cells identifies a differential response to nucleosome depletion. Cell Cycle. 2017;16:189-199 pubmed publisher

Ohashi T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Imamura T, et al. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma. Br J Cancer. 2017;116:218-226 pubmed publisher

Gong L, Pan X, Chen H, Rao L, Zeng Y, Hang H, et al. p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming. Sci Rep. 2016;6:37281 pubmed publisher

Alfano L, Costa C, Caporaso A, Antonini D, Giordano A, Pentimalli F. HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation. Oncotarget. 2016;7:78127-78139 pubmed publisher

Tran T, Lowman X, Reid M, Mendez Dorantes C, Pan M, Yang Y, et al. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction. Oncogene. 2017;36:1991-2001 pubmed publisher

Moureau S, Luessing J, Harte E, Voisin M, Lowndes N. A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining. Open Biol. 2016;6: pubmed

Yang C, Zhou Q, Li M, Tong X, Sun J, Qing Y, et al. Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines. Sci Rep. 2016;6:33078 pubmed publisher

Monteith J, Mellert H, Sammons M, Kuswanto L, Sykes S, Resnick Silverman L, et al. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Mol Oncol. 2016;10:1207-20 pubmed publisher

Hong A, Tseng Y, Cowley G, Jonas O, Cheah J, Kynnap B, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016;7:11987 pubmed publisher

Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, et al. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. 2016;23:1615-27 pubmed publisher

López Mateo I, Arruabarrena Aristorena A, Artaza Irigaray C, López J, Calvo E, Belandia B. HEY1 functions are regulated by its phosphorylation at Ser-68. Biosci Rep. 2016;36: pubmed publisher

Shin M, He Y, Marrogi E, Piperdi S, Ren L, Khanna C, et al. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells. PLoS Genet. 2016;12:e1005884 pubmed publisher

Swetzig W, Wang J, Das G. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget. 2016;7:16049-69 pubmed publisher

Talarico C, Dattilo V, D Antona L, Barone A, Amodio N, Belviso S, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget. 2016;7:15868-84 pubmed publisher

Iyer S, Parrales A, Begani P, Narkar A, Adhikari A, Martinez L, et al. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget. 2016;7:5401-15 pubmed publisher

Li Z, Hao Q, Luo J, Xiong J, Zhang S, Wang T, et al. USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene. 2016;35:2902-12 pubmed publisher

Bailey M, Singh T, Mero P, Moffat J, Hieter P. Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint. Genetics. 2015;201:885-95 pubmed publisher

Hünten S, Hermeking H. p53 directly activates cystatin D/CST5 to mediate mesenchymal-epithelial transition: a possible link to tumor suppression by vitamin D3. Oncotarget. 2015;6:15842-56 pubmed

Sharma V, Jordan J, Ciribilli Y, Resnick M, Bisio A, Inga A. Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay. PLoS ONE. 2015;10:e0130170 pubmed publisher

Marchesini M, Matocci R, Tasselli L, Cambiaghi V, Orleth A, Furia L, et al. PML is required for telomere stability in non-neoplastic human cells. Oncogene. 2016;35:1811-21 pubmed publisher

Pishas K, Adwal A, Neuhaus S, Clayer M, Farshid G, Staudacher A, et al. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep. 2015;5:11465 pubmed publisher

Pfister N, Fomin V, Regunath K, Zhou J, Zhou W, Silwal Pandit L, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015;29:1298-315 pubmed publisher

Petroni M, Sardina F, Heil C, Sahún Roncero M, Colicchia V, Veschi V, et al. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. Cell Death Differ. 2016;23:197-206 pubmed publisher

Sokka M, Rilla K, Miinalainen I, Pospiech H, Syväoja J. High levels of TopBP1 induce ATR-dependent shut-down of rRNA transcription and nucleolar segregation. Nucleic Acids Res. 2015;43:4975-89 pubmed publisher

Cui H, Guo M, Xu D, Ding Z, Zhou G, Ding H, et al. The stress-responsive gene ATF3 regulates the histone acetyltransferase Tip60. Nat Commun. 2015;6:6752 pubmed publisher

Chen Y, Wright J, Meng X, Leppard K. Promyelocytic Leukemia Protein Isoform II Promotes Transcription Factor Recruitment To Activate Interferon Beta and Interferon-Responsive Gene Expression. Mol Cell Biol. 2015;35:1660-72 pubmed publisher

Brazina J, Svadlenka J, Macurek L, Andera L, Hodny Z, Bartek J, et al. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase. Cell Cycle. 2015;14:375-87 pubmed publisher

Müllers E, Silva Cascales H, Jaiswal H, Saurin A, Lindqvist A. Nuclear translocation of Cyclin B1 marks the restriction point for terminal cell cycle exit in G2 phase. Cell Cycle. 2014;13:2733-43 pubmed publisher

Iannetti A, Ledoux A, Tudhope S, Sellier H, Zhao B, Mowla S, et al. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence. PLoS Genet. 2014;10:e1004642 pubmed publisher

Maya Mendoza A, Merchut Maya J, Bartkova J, Bartek J, Streuli C, Jackson D. Immortalised breast epithelia survive prolonged DNA replication stress and return to cycle from a senescent-like state. Cell Death Dis. 2014;5:e1351 pubmed publisher

Weilbacher A, Gutekunst M, Oren M, Aulitzky W, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014;5:e1318 pubmed publisher

Loughery J, Cox M, Smith L, Meek D. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 2014;42:7666-80 pubmed publisher

Charles J, Fuchs J, Hefter M, Vischedyk J, Kleint M, Vogiatzi F, et al. Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nat Commun. 2014;5:3981 pubmed publisher

Jung H, Phillips B, Chan E. miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3?. Mol Cancer. 2014;13:80 pubmed publisher

Busch M, Schwindt H, Brandt A, Beier M, Görldt N, Romaniuk P, et al. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation. Hum Mol Genet. 2014;23:3958-74 pubmed publisher

Laget S, Miotto B, Chin H, Esteve P, Roberts R, Pradhan S, et al. MBD4 cooperates with DNMT1 to mediate methyl-DNA repression and protects mammalian cells from oxidative stress. Epigenetics. 2014;9:546-56 pubmed publisher

Miki T, Matsumoto T, Zhao Z, Lee C. p53 regulates Period2 expression and the circadian clock. Nat Commun. 2013;4:2444 pubmed publisher

Kleiblova P, Shaltiël I, Benada J, Sevcik J, Pecháčková S, Pohlreich P, et al. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol. 2013;201:511-21 pubmed publisher

Madar S, Harel E, Goldstein I, Stein Y, Kogan Sakin I, Kamer I, et al. Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta. PLoS ONE. 2013;8:e61353 pubmed publisher

Huang L, Jin J, Deighan P, Kiner E, McReynolds L, Lieberman J. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013;31:350-6 pubmed publisher

Sachweh M, Drummond C, Higgins M, Campbell J, Lain S. Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 2013;4:e533 pubmed publisher

Singh S, Raina V, Chavali P, Dubash T, Kadreppa S, Parab P, et al. Regulation of GAD65 expression by SMAR1 and p53 upon Streptozotocin treatment. BMC Mol Biol. 2012;13:28 pubmed

Lee J, Kang S, Jeon Y, Park J, You J, Ha S, et al. Protein L-isoaspartyl methyltransferase regulates p53 activity. Nat Commun. 2012;3:927 pubmed publisher

Kim T, Oh S, Shin S, Janknecht R. Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS ONE. 2012;7:e34618 pubmed publisher

Léveillé N, Elkon R, Davalos V, Manoharan V, Hollingworth D, Oude Vrielink J, et al. Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun. 2011;2:513 pubmed publisher

Aranha M, Santos D, Sola S, Steer C, Rodrigues C. miR-34a regulates mouse neural stem cell differentiation. PLoS ONE. 2011;6:e21396 pubmed publisher

Muenyi C, States V, Masters J, Fan T, Helm C, States J. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J Ovarian Res. 2011;4:9 pubmed publisher

Sankala H, Vaughan C, Wang J, Deb S, Graves P. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys. 2011;512:52-60 pubmed publisher

Li Y, Zhu Z, Zhang S, Yu D, Yu H, Liu L, et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS ONE. 2011;6:e17794 pubmed publisher

Taura M, Suico M, Fukuda R, Koga T, Shuto T, Sato T, et al. MEF/ELF4 transactivation by E2F1 is inhibited by p53. Nucleic Acids Res. 2011;39:76-88 pubmed publisher

Jun J, Lau L. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol. 2010;12:676-85 pubmed publisher

de Bruijn M, Raats D, Hoogwater F, van Houdt W, Cameron K, Medema J, et al. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer. 2010;102:1254-64 pubmed publisher

Aylon Y, Yabuta N, Besserglick H, Buganim Y, Rotter V, Nojima H, et al. Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene. 2009;28:4469-79 pubmed publisher

Ting A, Low G, Gopalakrishnan K, Hande M. Telomere attrition and genomic instability in xeroderma pigmentosum type-b deficient fibroblasts under oxidative stress. J Cell Mol Med. 2010;14:403-16 pubmed publisher

Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol. 2007;178:23-30 pubmed

Zaika A, Slade N, Erster S, Sansome C, Joseph T, Pearl M, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med. 2002;196:765-80 pubmed

Fish K, Schmid S, Damke H. Evidence that dynamin-2 functions as a signal-transducing GTPase. J Cell Biol. 2000;150:145-54 pubmed